Mon, Jan 26, 2015, 10:27 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Calmare Therapeutics Incorporated Message Board

  • favela808 favela808 Nov 1, 2011 1:53 AM Flag

    Mayo Clinic

    Subject: Mayo Clinic Comments-Poster Session on Calmare-CONCLUSION: Strong preliminary data support further investigation of scrambler therapy
    Date: Mon, 31 Oct 2011

    These are the 1st public comments from the Mayo Clinic regarding Calmare:

    Abstract PA-2: Evaluating a Novel Device for the
    Treatment of Chemotherapy-Induced Peripheral
    Neuropathy



    BACKGROUND: Chemotherapy-induced peripheral neuropathy
    (CIPN) is a common and dose limiting side effect of chemotherapy. Multiple therapies have been investigated for the treatment
    of CIPN, however, there are no proven effective interventions.
    Scrambler therapy (MC5-A) is designed to treat pain via non-invasive cutaneous electrostimulation. The device substitutes “pain”
    information with “non-pain” information by generating 16 different current patterns, which simulate nerve action potentials. Five
    small trials have reported the efficacy of MC5-A in the treatment
    of various forms of neuropathic and cancer-related pain. One pilot trial assessed efficacy of scrambler therapy in CIPN. Patients
    treated with 10 sessions of scrambler therapy had a decrease in
    pain score of 59%. However, scrambler therapy has never been
    tested against a sham therapy and there is still much to learn about
    its clinical effects and mechanism of action. OBJECTIVE: Two pilot trials will be done to obtain prospective pilot experience with
    MC5-A with regard to treatment efficacy, compared to a sham,
    and tolerability. METHODS: Each pilot trial will involve 10 patients
    with CIPN. Inclusion criteria include symptoms of peripheral
    neuropathy t1 month, and pain, numbness, or tingling rated t
    4/10 during the prior week. Sham therapies include: 1) electrodes
    placed on the back compared to the legs, and 2) a TENS machine
    on the lower extremities. RESULTS: This poster will provide an
    overview of a novel potential therapy (MC5-A), showing pictures
    of the device and treatment algorithm. LIMITATIONS: These studies are in progress. CONCLUSION: Strong preliminary data support
    further investigation of scrambler therapy. KEYWORDS: chemotherapy-induced peripheral neuropathy, pain, neuropathy, scrambler
    therapy, neurocutaneous stimulation
    CORRESPONDING AUTHOR: Deirdre R. Pachman, MD
    CONFLICTS OF INTEREST: The corresponding author has no con-
    flicts of interest to report.


    Pachman DR, MD1
    , Barton DL, RN, PhD2
    , Linquist BM, RN 2
    ,
    Fee-Schroeder KC, RN2
    , Lachance DH, MD3
    , Loprinzi CL, MD2
    1
    Department of Medicine, Mayo Clinic, Rochester, MN
    2
    Department of Oncology, Mayo Clinic, Rochester, MN
    3
    Department of Neurology, Mayo Clinic, Rochester, MN

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I see the paranoia hasn't gone away.How about that 52 week high?

    • ...HAW!!!...that cracks me up!...I point out in a half-dozen places how electrodes or whatever on the back doesn't constitute a control for the bugzapper and low and behold suddenly a TENS on the lower extremities appears!...good to know someone's paying attention!...but still, that really ISN'T a control to demonstrate efficacy of the bugzapper...

      ...HOWEVER, it may demonstrate whether the bugzapper is superior to a TENS device...problem, though, are those TEN patients...TEN?...PLUS dividing them into two separate groups?...FIVE patients per group?...why not FORTY patients?...or more?...we're not talking about a complicated procedure, right?...and it ain't a real expensive procedure to carry out -- right?...

      ...and presumably they want to maximize the probability of showing any differences between groups aren't due to simple random variations in the population...and doing it right the FIRST time would be for the best -- don't you think?...and five patients is going to make that kinda tough...

      ...and without some significant differences, insurance companies probably aren't going to get real excited about coughing up 1500-2500 bucks when you can buy a TENS off Amazon for 30-50 bucks...

    • I thought it difficult to do a sham, what with the need for patient feedback at the time of electrode placement. The use of a tens macine that looks like a Calmare machine solves that problem in that they both reduce pain but the tens doesn't last. This should silence the naysayers. (NOT)

      • 2 Replies to sharkriver100
      • Nothing will silence the naysayer. Look for him to just quietly disappear. Something is brewing and about to be released. Unfortunately it is hard to pick up this stock in any volume without driving up the price. I only need a few thousand more to be happy, but it looks like there is a stronger buyer out there. Seems like they know something. I even tried selling off a few thousand shares to try and scare them off, but I ended up having to buy back a few cents higher. So no more messing around--if I can't get the shares I want at the price I want I will just have to wait longer, or pay more.

      • Over at IH it was pointed out that since Mayo includes TENS as one of their sham protocols this might silence those who claim Calmare is just a fancy Italian word for TENS

 
CTTC
0.170.00(+0.06%)Jan 26 3:48 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.